NOCOB Enterprises

NOCOB Enterprises is a biotechnology company focused on the development of novel therapeutic agents for the treatment of chronic cough, pain, and inflammatory conditions. The company's research centers on the modulation of specific sodium channels, particularly Nav1.7 and Nav1.8, to selectively inhibit pain-sensing neurons without affecting motor or sensory functions. By leveraging its expertise in neuropharmacology, NOCOB Enterprises aims to provide safer and more effective alternatives to current opioid-based treatments. The company is currently advancing several small molecule candidates through pre-clinical development to address significant unmet needs in respiratory and neurological health.